Phase 1, Multiple Ascending Dose Study of Anti-HER2 FCAB FS102 in HER2 Posivie Solid Tumors

Trial Profile

Phase 1, Multiple Ascending Dose Study of Anti-HER2 FCAB FS102 in HER2 Posivie Solid Tumors

Completed
Phase of Trial: Phase I

Latest Information Update: 04 Aug 2017

At a glance

  • Drugs FS 102 (Primary)
  • Indications Adenocarcinoma; Breast cancer; Gastric cancer; Solid tumours
  • Focus Adverse reactions
  • Sponsors Bristol-Myers Squibb; F-star Alpha
  • Most Recent Events

    • 18 Jul 2017 Status changed from active, no longer recruiting to completed.
    • 19 Apr 2017 Status changed from recruiting to active, no longer recruiting.
    • 13 May 2016 Planned End Date changed from 1 Dec 2016 to 1 Jun 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top